Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation

Table 5 Comparison of doses to iliac and lower pelvic bone marrow (defined with ¹⁸FDG-PET) among the 4 plans

		Plan A		Plan B		Plan C		Plan D		p ≤ 0.05 ANOVA
Structure	Parameter	Mean	SD(+/−)	Mean	SD(+/−)	Mean	SD(+/−)	Mean	SD(+/−)
^ACTIBM	D _max	48.19	3.11	48.34	3.22	48.77	3.21	48.68	3.37	NS
	D _mean	24.44	6.63	24.22	2.56	22.28	3.65	22.63	3.62	NS
	V ₅	96.74	4.70	96.20	6.16	95.82	6.27	95.52	6.66	NS
	V ₁₀	90.99	8.49	89.74	9.65	87.22	12.22	87.89	11.38	NS
	V ₁₅	84.31	10.64	81.75	12.04	74.75	17.13	76.28	16.98	NS
	V ₂₀	66.15	9.73	65.45	11.85	55.52	15.35	57.14	15.83	NS
	V ₂₅	45.84	8.97	46.28	9.29	37.87	11.85	37.80	12.04	NS
	V ₃₀	29.15	8.09	30.23	5.82	23.82	8.82	24.89	9.31	NS
	V ₃₅	16.43	6.62	16.82	4.14	13.33	5.82	14.75	5.98	NS
	V ₄₀	7.48	4.37	6.61	3.19	5.95	3.24	6.67	3.13	NS
	V ₄₅	0.94	1.57	0.93	1.86	1.02	1.24	1.05	1.46	NS
^ACTLPBM	D _max	52.66	2.71	52.93	2.82	53.00	2.86	53.14	2.70	NS
	D _mean	33.09	4.61	30.63	4.70	29.34	4.80	29.54	4.63	NS
	V ₅	98.30	3.37	96.93	5.11	97.15	5.66	98.01	4.14	NS
	V ₁₀	90.09	9.01	88.32	9.85	89.50	9.28	88.95	10.05	NS
	V ₁₅	86.12	10.76	82.13	12.69	80.73	14.49	81.07	12.61	NS
	V ₂₀	82.07	12.89	76.19	13.85	71.53	15.41	72.34	14.82	NS
	V ₂₅	75.68	14.62	67.33	14.57	61.89	15.33	63.45	15.46	NS
	V ₃₀	66.78	15.38	57.91	14.86	51.34	13.93	52.29	14.28	NS
	V ₃₅	55.63	15.81	46.22	13.29	40.63	12.42	41.33	12.55	NS
	V ₄₀	38.94	12.30	32.28	10.88	29.06	10.86	29.37	10.56	NS
	V ₄₅	16.98	7.53	14.15	6.52	13.54	7.12	12.89	8.85	NS

Legend: D _max maximal dose, D _mean mean dose, SD standard deviation, V _{5,10,15,20,25,30,35,40,45} relative volume receiving 5,10,15,20,25,30,35,40,45 Gy, IBM iliac bone marrow, LPBM lower pelvis bone marrow, ^ACT active, A, B, C plan A, B, C, NS non significant

ISSN: 1471-2407